LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (www.Goldberglapwc.com) announces that it is investigating claims of potential misrepresentations by IsoRay, Inc. (“IsoRay” or the “Company”) (NYSE: ISR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased or otherwise acquired IsoRay shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.
IsoRay manufactures isotope-based medical products for the treatment of cancer and other malignant diseases. The Company produces Proxcelan Cesium-131 brachytherapy seeds for the treatment of various cancers. On May 20, 2015, the Company issued a press release touting the publication of the first major peer reviewed study of Cesium-131 seeds for the treatment of non-small cell lung cancers. However, on May 21, 2015, TheStreet.com published an article claiming that IsoRay selectively edited findings from the study, making the product appear better than it was. The author of the article, Adam Feuerstein, stated that he did not consider the results of the study to be “outstanding.” As a result of this news, shares of IsoRay fell over 35% on May 21, 2015, to close at $2.02 per share.
If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
